Comparison of the Effects of Prophylactic and Therapeutic
                    Administrations on Peripheral Neuropathy in Streptozotocin-Diabetic Rats with
                    Gliclazide or Methylcobalamin

Hongping Yao; Juanyi Feng; Qiaowei Zheng; Youxia Wei; Guangde Yang; Weiyi Feng

doi:10.1055/a-0635-0672

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2020; 128(10): 635-643
DOI: 10.1055/a-0635-0672

Article

Comparison of the Effects of Prophylactic and Therapeutic Administrations on Peripheral Neuropathy in Streptozotocin-Diabetic Rats with Gliclazide or Methylcobalamin

Hongping Yao

¹First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, China

,

Juanyi Feng

²Second Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, China

,

Qiaowei Zheng

¹First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, China

,

Youxia Wei

¹First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, China

,

Guangde Yang

³Department of Pharmacology, Medical College of Xi’an Jiaotong University, Xi’an, China

,

Weiyi Feng

¹First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, China

› Author Affiliations

Abstract

Objective To observe the differences in curative effects between prophylactic and therapeutic administrations of Gliclazide (GLZ) or Methylcobalamin (MCA) on diabetic peripheral neuropathy in rats.

Methods GLZ (25 mg/kg/day) or MCA (175 μg/kg/day) was orally administrated prophylactically to streptozotocin-induced diabetic rats for 8 weeks before diabetic peripheral neuropathy developed or administrated therapeutically after diabetic peripheral neuropathy developed, respectively. The motor nerve conduction velocities (MNCV), aldose reductase (AR) activities, the polyol contents and antioxidative enzyme activities in the sciatic never tissues were determined. The morphology of sciatic never tissues was observed.

Results In comparison to vehicle, most of the changes in the sciatic nerves of the diabetic rats (e. g., delayed MNCV, altered/damaged nerve structure, enhanced AR activity, increased polyol contents, altered Cu, Zn-superoxide dismutase, glutathione-peroxidase activities, and elevated malondialdehyde level) were significantly ameliorated by prophylactic administration with either GLZ or MCA. In contrast, only few of above-mentioned parameters were alleviated in DPN rats by therapeutic administration with GLZ or MCA as compared to vehicle. The curative effects of GLZ or MCA prophylactic administration on MNCV, AR activity, polyol contents and antioxidative enzyme activities were markedly stronger than therapeutic administration.

Conclusion Prophylactic administration of GLZ or MCA was superior to the therapeutic administration in alleviation of diabetic neuropathy in STZ-rats, suggesting that pharmacotherapy should be initiated at a much earlier stage before diabetic neuropathy developed, but not at a later stage after never damage reached.

Key words

diabetic peripheral neuropathy - prophylactic administration - therapeutic administration

Full Text

References

References
1 Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy–acontinuing enigma. Diabetes Metab Res Rev 2000; 16: 408-433
2 Miranda-Massaril JR, Gonzalez MJ, Jimenez FJ. et al. Neuropathy: Improving clinical results beyond symptom control. Curr Clin Pharmacol 2011; 6: 260-273
3 Li S, Chen X, Li Q. et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig 2016; 7: 777-785
4 Boucek P. Advanced diabetic neuropathy: A point of no return?. The Review of Diabetic Studies 2006; 3: 143-150
5 Albers JW. Rodica Pop-Busui. Diabetic neuropathy: Mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014; 14: 473-485
6 Kern TS, Tang J, Berkowitz BA. Validation of structural and functional lesions of diabetic retinopathy in mice. Mol Vis. 2010; 16: 2121-2131
7 Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-1070
8 Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient. Exp Diabetes Res 2007; 2007: 1-10
9 Li Q-r, Wang Z, Zhou W. et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res 2016; 11: 345-351
10 Sima AA, Sugimoto K. Experimental diabetic neuropathy: An update. Diabetologia 1999; 42: 773-788
11 Morre DM, Lenaz G, Morre DJ. Surface oxidase and oxidative stress propagation in aging. J. Exp. Biol. 2000; 203: 1513-1521
12 Kasznicki J, Kosmalski M, Sliwinska A. et al. Evaluation of oxidative stress markers in pathogenesisof diabetic neuropathy. MolBiol Rep 2012; 39: 8669-8678
13 Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007; 87: 245-313
14 Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res 2013; 1-8
15 Bandeira SDM, da Fonseca LJS, Guedes GDS. et al. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. Int J Mol Sci. 2013; 14: 3265-3284
16 Oyenihi AB, Ayeleso AO, Mukwevho E. et al. Antioxidant strategies in the management of diabetic neuropathy. Biomed Res Int. 2015; 1-15
17 Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2diabetes. mellitus World J Diabetes 2015; 6: 456-480
18 Scott NA, Jennings PE, Brown J. et al. Gliclazide: A general free radical scavenger. Eur J Pharmacol 1991; 208: 175-177
19 Desfaits AC, Serri O, Renier G. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metabolism 1997; 46: 1150-1156
20 Renier G, Desfaits AC, Serri O. Effect of gliclazide on monocyte-endothelium interactions in diabetes. J. Diabetes Complications 2000; 14: 215-223
21 Jennings PE, Belch JJ. Free radical scavenging activity of sulfonylureas: A clinical assessment of the effect of gliclazide. Metabolism 2000; 49: 23-26
22 Kimoto K, Suzuki K, Kizaki T. et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem. Biophys. Res. Commun. 2003; 303: 112-119
23 O'Brien RC, Luo M, Balazs N. et al. In vitro and in vivo antioxidant properties of gliclazide. J. Diabetes Complications 2000; 14: 201-206
24 Wu YB, Shi LL, Wu YJ. et al. Protective effect of gliclazide on diabetic peripheral neuropathy through Drp-1 mediated-oxidative stress and apoptosis. Neurosci Lett 2012; 523: 45-49
25 Zhang YF, Ning G. Mecobalamin. Expert Opin Investig Drugs 2008; 17: 953-964
26 Koyama K, Usami T, Takeuchi O. et al. Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Nephrol Dial Transplant 2002; 17: 916-922
27 Head KA. Peripheral neuropathy: Pathogenic mechanisms and alternative therapies. Altern Med Rev 2006; 11: 294-329
28 Kuwabara S, Nakazawa R, Azuma N. et al. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med 1999; 38: 472-475
29 Feng W, Hou J, Wang J. et al. Effects of methylcobalamin, gliclazide and their combination on peripheral nerve function and polyol pathway in streptozotocin diabetic rats. Chin Pharmacol J 2004; 39: 27-30
30 Feng W, Yao H, Wei Y. et al. Effect of methylcobalam, gliclazide and combined application of both on sciatic nerve morphology and nerve growth factor contents in streptozotocin-induced diabetic rats. Chin Pharmacol Bull 2009; 25: 1308-1312
31 Pop-Busui R, Sullivan KA, Van HC. et al. Depletion of taurine in experimental diabetic neuropathy: Implications for nerve metabolic, vascular, and functional deficits. Exp Neurol 2001; 168: 259-272
32 Kakkar R, Mantha SV, Radhi J. et al. Antioxidant defense system in diabetic kidney: A time course study. Life Sci 1997; 60: 667-679
33 AeBi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-126
34 Coppey LJ, Davidson EP, Dunlap JA. et al. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Experimental Diab Res 2000; 1: 131-143
35 Shen Z, WU S, Shao F. et al. Diabetic Chronic Complications[M].1st. Shanghai Medical University Press; Shanghai: 1999: 231-249
36 Chung SSM, Ho ECM, Lam KSL. et al. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am SocNephrol 2003; 14: 233-S236
37 Tang WH, Martin KA, Hwa J. et al. Aldose reductase, oxidative stress, and diabetes mellitus. Aldose Reductase And Diabetes Mellitus 2012; 3: 1-8
38 Williamson JR, Chang K, Frangos M. et al. “Hyperglycemic Pseudohypoxia and diabetic complications,”. Diabetes 1993; 42: 801-813
39 Babizhayev MA, Vishnyakova KS, Yegorov YE. Oxidative damage impact on aging and age-related diseases: Drug targeting of telomere attrition and dynamic telomerase activity flirting with imidazole-containing dipeptides. Recent Pat Drug Deliv Formul 2014; 8: 163-192
40 Bukan N, Sancak B, Yavuz O. et al Lipid peroxidation and scavenging enzyme levels in the liver of streptozotocin-induced diabetic rats. Indian J. Biochem.Biophys. 2003; 40: 447-450
41 Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol. 2002; 15: 595-603
42 Obrosova IG, Van Huysen C, Fathallah L. et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J. 2002; 16: 123-125